Φορτώνει......

Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma

Prior to the advent of VEGF-targeted therapies, renal cell carcinoma (RCC) was among the few solid tumors shown to respond to cytokine-based therapies such as interleukin-2 (IL-2) and interferon alpha. Previous work has shown that aminobisphosphonates, including zoledronic acid (ZA), are capable of...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Lang, Joshua M., Kaikobad, Mahazarin R., Wallace, Marianne, Staab, Mary Jane, Horvath, Dorothea L., Wilding, George, Liu, Glenn, Eickhoff, Jens C., McNeel, Douglas G., Malkovsky, Miroslav
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2011
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3177972/
https://ncbi.nlm.nih.gov/pubmed/21647691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-011-1049-8
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!